Time is a critical factor in evaluating indirect hERG inhibition by
Oligonucleotide Therapeutics
Abstract
Background and Purpose: In accord with ICH S7B guidelines, an in vitro
human ether-a-go-go-related gene (hERG) assay is conducted to assess
risk for delayed ventricular repolarization. Function of hERG could be
affected by direct and acute mechanisms, or by indirect and chronic
mechanisms. Oligonucleotides have unique mechanisms and time courses of
action. To help frame the strategy of hERG assay for siRNA,
investigation was performed to assess the time-course for siRNA-mediated
inhibition of hERG function and gene expression. Experimental Approach:
Commercially available siRNAs of hERG were evaluated in a stable hERG
expressed cell line by whole-cell voltage clamp using automated
electrophysiology and polymerase chain reaction (PCR). Key Results: In
the acute hERG study, no effects were observed by applying 100 nM siRNA
for 20 min. The chronic effects of 100 nM siRNAs on hERG function were
evaluated by transfection and recorded over 8-48 hrs, after
transfection. At 8 hrs there was no significant effect, while 81%
reduction was observed at 48 hrs. Measurement of hERG mRNA levels
demonstrated a 79% and 93% decrease of hERG mRNA at 8 and 48 hrs.,
respectively, consistent with a preceding effect on gene expression
compared to protein function. Conclusion and Implications: Results
presented here indicate that an anti-hERG siRNA requires a long exposure
time (48 hrs.) in the hERG assay to produce a maximal effect; short
exposures (20 min-8 hrs.) had no effect. These findings imply that
oligonucleotides require specific and appropriate protocols to
characterize their potential off-target effects on hERG channel.